We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Edwards Lifesciences says that a clinical trial found favorable patient outcomes after six months for its investigational Evoque transcatheter, transfemoral, tricuspid valve-replacement system. Read More
Swiss company Alcon is paying $475 million to acquire device company Ivantis, developer of the Hydrus Microstent for surgical glaucoma, strengthening Alcon’s ophthalmology portfolio. Read More
A bipartisan group of 10 senators has asked the Centers for Medicare & Medicaid Services (CMS) to find a way to pay for breakthrough devices, after the agency withdrew its previous proposal to do so. Read More
Abbott’s MitraClip G4 reduced mitral regurgitation (MR) in a clinical trial to one or fewer in 91 percent of patients and significantly improved their New York Heart Association classification and quality of life, the company said last week. Read More
Penumbra’s Indigo System CAT RX catheter met the primary endpoint in the “Cheetah” postmarket clinical study, demonstrating high rates of blood clot removal, blood flow restoration and myocardial perfusion in conjunction with percutaneous coronary intervention in patients with high thrombus burden, the company said Friday. Read More
Liquidia has grabbed tentative FDA approval for Yutrepia, the first inhalation powder form of treprostinil, a vasodilator used in other forms to treat pulmonary hypertension. Read More